Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion and NRT for Smoking Cessation in Hospitalized Patients
NCT06254001Phase 4Recruiting
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupropion in Tobacco Use Disorder (TUD) (2 arms), sponsored by Instituto Nacional de Enfermedades Respiratorias. Primary endpoint: Abstinence at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
bupropion
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06254001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254001.